Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes

Acta Haematologica

Volumn 120, Issue 2, 2008, Pages 104-107

  Latagliata, R ^a   Oliva, E N ^b   Volpicelli, P ^a   Carmosino, I ^a   Breccia, M ^a   Vincelli, I ^b   Alati, C ^b   Napoleone, L ^a   Vozella, F ^a   Nobile, F ^b   Alimena, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANEMIA; CYTOGENETIC ANALYSIS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 54949140003     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000166864     Document Type: Article

References (15)

1. Cazzola M, Anderson JE, Ganser A, Hellstrom-Lindberg E: A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 1998;83:910-935.
2. Bennett JM: World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 2000;72:131-133.
3. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
4. Oliva EN, D'Angelo A, Martino B, Nobile F, Dimitrov BD, Perna A: More concern about transfusion requirement when evaluating quality of life in anemic patients. J Clin Oncol 2002;14:3182-3184.
5. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-7603.
6. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-3510.
7. Italian Cooperative Study Group for rHu-EPO in myelodyspastic syndromes: A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low risk myelodysplastic syndromes. Br J Haematol 1998;103:1070-1074.
8. Terpos E, Mougiou A, Kouraklis A, Chatzivassili A, Michalis E, Giannakoulas N, Manioudaki E, Lazaridou A, Bakaloudi V, Protopappa M, Liapi D, Grouzi E, Parharidou A, Symeonidis A, Kokkini G, Laoutaris NP, Vaipoulos G, Anagnostopoulos NI, Christakis JI, Meletis J, Bourantas KL, Zoumbos NC, Yataganas X, Viniou NA, Greek MDS Study Group: Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002;118:174-180.
9. Musto P, Falcone A, Sanpaolo G, Bodenizza C, La Sala A, Perla G, Carella AM: Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol 2003;122:269-271.
10. Ross SD, Allen IE, Probst CA, Sercus B, Crean SM, Ranganathan G: Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 2007;12:1264-1273.
11. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarrè MC, Damaj G, Giraudier S, Guerci A, Laurent G, Dombret H, Chomienne C, Ribrag V, Stamatoullas A, Marie JP, Vekhoff A, Maloisel F, Navarro R, Dreyfus F, Fenaux P: Health, economic and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004;104:321-327.
12. Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, Volpe E, Clavio M, Grossi A, Reyes MT, Musto P, Mitra ME, Azzarà A, Pagnini D, D'Arena G, Spadano A, Balleari E, Pecorari P, Capochiani E, De Biasi E, Perego D, Monarca B, Pisani F, Scaramella G, Petti MC: Impact of a new dosing regimen of epoetin alfa on quality of life and anaemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 2005;84:167-176.
13. Cheson BD, Bennett JM, Kantarijan H, Pinto A, Schiffer CA, Nimer SD, Löwenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL, World Health Organization(WHO) International Working Group: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-3674.
14. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel MT, Cheze S, Mahé B, Ferrant A, Ravoet C, Escoffre-Barbe M, Adès L, Vey N, Aljassem L, Stamatoullas A, Mannone L, Dombret H, Bourgeois K, Greenberg P, Fenaux P, Dreyfus F, GFM group (Groupe Francophone des Myélodysplasies): Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008;111:574-582.
15. Wallvik J, Stenke L, Bernell P, Nordahl G, Hippe E, Hast R: Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol 2002;68:180-186.